Bayer Join Forces with Cytokinetics to Develop and Commercialize Aficamten in Japan
Shots:
- Bayer and Cytokinetics have partnered to develop and commercialize aficamten in Japan, combining Cytokinetics’ development program with Bayer’s regional cardiology expertise
- Bayer will handle the P-III trial for obstructive HCM in Japan, while Cytokinetics will extend the ongoing P-III (ACACIA-HCM) trial in non-obstructive HCM patients & CEDAR-HCM for pediatric population with obstructive HCM into Japan to support marketing approval. Cytokinetics plans to file MAA to the EMA in Q4’24
- Cytokinetics is eligible for ~$52.76M (€50M) upfront, additional ~$94.97M (€90M) milestones through commercial launch [incl. ~$21.10M (€20M) near-term], ~$517.15M (€490M) sales milestones and net-sales-based tiered royalties in Japan
Ref: Bayer | Image: Bayer & Cytokinetics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
